An FDA Panel Meets Nov. 19 on Pathogen-Agnostic Sequencing for Outbreaks. Requests to Speak Are Due Oct. 28.
The Microbiology Devices Panel will advise the Food and Drug Administration on tests that sequence whatever is in a sample, for known or unknown pathogens in an outbreak. Comments received by Nov. 3 go to the panel; the docket closes Nov. 12.
The Food and Drug Administration's Microbiology Devices Panel meets Nov. 19 to advise the agency on pathogen-agnostic sequencing for emergency preparedness and response, and anyone who wants to speak at the meeting must ask by Oct. 28.
Pathogen-agnostic sequencing means testing that sequences whatever genetic material is in a sample rather than looking for a named organism. The FDA's meeting page says the session runs from 9 a.m. to 4 p.m. Eastern in the Great Room of the Building 31 Conference Center on the White Oak campus in Silver Spring, Maryland, with a YouTube webcast for remote viewers.
What is the panel being asked to consider?
The panel will discuss the scientific, clinical and public health dimensions of using pathogen-agnostic sequencing in outbreaks, along with opportunities, implementation considerations and potential priorities for future coordination. The Federal Register notice, published Sept. 16, says the preparedness use could cover local outbreaks, national outbreaks, known pathogens or unknown pathogens.
The FDA is seeking input on how these tests should be designed and on the opportunities and challenges in developing them, "including how to establish an agile but effective and validated bioinformatics system that can account for frequent sequence changes." The meeting is held to satisfy, in part, a requirement of the Food and Drug Omnibus Reform Act of 2022 (FDORA). Like all advisory committee advice, the panel's recommendations are not binding on the agency.
For a clinical lab or infectious disease service, the hard question is not whether a sequencer can read a sample but who validates the software that interprets it when the pathogen is unexpected.
How can clinicians weigh in?
There are three routes, each with its own date. Written comments go to Docket FDA-2026-N-8692 at regulations.gov; those received by Nov. 3 will be given to the committee, and later ones will be considered by the FDA but not sent to the panel. The docket closes at 11:59 p.m. Eastern on Nov. 12, and late comments will not be considered.
Oral presentations will be scheduled between about 1 p.m. and 2 p.m. Eastern. Anyone who wants a slot must notify the contact person, Evella Washington of the FDA's Advisory Committee Oversight Management Staff, by Oct. 28 with a brief statement of the evidence or arguments to be presented, the names and addresses of presenters, whether they will appear online or in person and the time requested. If more people ask than the session can hold, the FDA may run a lottery, and requesters will be notified by Oct. 30.
Comments are posted publicly, so the notice warns against including medical information or other confidential details in the body of a comment; confidential material goes by paper submission instead.
What to watch
The meeting page lists no discussion questions yet. The notice says the FDA intends to post background material no later than two business days before the meeting, and that briefing will show what performance and validation evidence the agency has in mind.
Nothing here changes how you order tests today. Infectious disease physicians, hospital epidemiologists and laboratory directors with views on turnaround time, interpretation and result reporting during an outbreak should file before Nov. 3 so the panel sees them. For how an unfamiliar pathogen can strain clinical workflows, see our Bundibugyo Ebola checklist.
Reported, fact-checked and edited by The Script Pad's editorial staff.
This article is for professional education and does not replace clinical judgment. Treatment decisions should be based on the individual patient and current guidelines.
